All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational Study
Open Access
- 9 April 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 72 (12), 2079-2086
- https://doi.org/10.1093/cid/ciaa413
Abstract
The impact of low levels of human immunodeficiency virus (HIV) RNA (low-level viremia [LLV]) during combination antiretroviral therapy (cART) on clinical outcomes is unclear. We explored the associations between LLV and all-cause mortality, AIDS, and serious non-AIDS events (SNAEs). We grouped individuals starting cART 1996–2017 (identified from the Swedish InfCare HIV register) as virologic suppression (VS; <50 copies/mL), LLV (repeated viral load, 50–999 copies/mL), and nonsuppressed viremia (NSV; ≥1000 copies/mL). Separately, LLV was subdivided into 50–199 and 200–999 copies/mL (reflecting different definitions of virologic failure). Proportional-hazard models (including sex, age, pre-ART CD4 count and viral load, country of birth, injection drug use, treatment experience and interruptions, and an interaction term between viremia and time) were fitted for the study outcomes. A total of 6956 participants were followed for a median of 5.7 years. At the end of follow-up, 60% were categorized as VS, 9% as LLV, and 31% as NSV. Compared with VS, LLV was associated with increased mortality (adjusted hazard ratio [aHR], 2.2; 95% confidence interval [CI], 1.3–3.6). This association was also observed for LLV 50–199 copies/mL (aHR, 2.2; 95% CI, 1.3–3.8), but was not statistically significant for LLV 200–999 copies/mL (aHR, 2.1; 95% CI, .96–4.7). LLV 50–999 copies/mL was not linked to increased risk of AIDS or SNAEs, but in subanalysis, LLV 200–999 copies/mL was associated with SNAEs (aHR, 2.0; 95% CI, 1.2–3.6). In this population-based cohort, LLV during cART was associated with adverse clinical outcomes.Keywords
Funding Information
- Physicians Against AIDS Research Foundation (FOa2019-0006)
- Gilead Nordic Fellowship (2018004132, ALFSUS- 40103, ALFGBG-717531, REGSKANE821541)
- Swedish Research Council (2016-01675)
This publication has 36 references indexed in Scilit:
- Low-Level Viremia Is Associated With Clinical Progression in HIV-Infected Patients Receiving Antiretroviral TreatmentJAIDS Journal of Acquired Immune Deficiency Syndromes, 2018
- Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatmentPLOS ONE, 2017
- Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohortThe Lancet Public Health, 2017
- Pro-Inflammatory Markers in Relation to Cardiovascular Disease in HIV Infection. A Systematic ReviewPLOS ONE, 2016
- Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patientsAIDS, 2015
- Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaborationThe Lancet, 2014
- Significance and Clinical Management of Persistent Low-Level Viremia and Very-Low-Level Viremia in HIV-1-Infected PatientsAntimicrobial Agents and Chemotherapy, 2014
- Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic ReviewPLOS ONE, 2013
- Mortality Attributable to Smoking Among HIV-1–Infected Individuals: A Nationwide, Population-Based Cohort StudyClinical Infectious Diseases, 2012
- CD4+ Count–Guided Interruption of Antiretroviral TreatmentThe New England Journal of Medicine, 2006